- Home
- Eurosurveillance
- Previous Issues
- Volume 30, Issue 6, 13/Feb/2025
Eurosurveillance - Volume 30, Issue 6, 13 February 2025
Volume 30, Issue 6, 2025
- Rapid communication
-
-
-
Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season
Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77–108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35–50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births.
-
-
-
Immediate public health surveillance response to cyclone Chido, Mayotte, 14 December 2024
On 14 December 2024, Cyclone Chido caused extensive damage to infrastructures in Mayotte, including water, electricity and communication networks. Health surveillance systems were no longer functional. Santé publique France provided health risk analyses to support local control measures. Malnutrition and dehydration, follow-up care, pregnancy and post-partum complications, mental health, gastrointestinal diseases, bacterial wound superinfections and bronchiolitis were the main risk identified. The preliminary ad hoc surveillance systems confirmed our analyses. We also present lessons learnt 1 month after the event.
-
-
-
Detections of rare enterovirus C105 linked to an emerging novel clade, Spain, 2019 to 2024
Enterovirus (EV)-C105 is a rare genotype not previously detected in Spain. Between 2019 and 2024, we detected EV-C105 in respiratory samples of five patients, through routine EV surveillance. Three cases had respiratory illness and two were hospitalised for neurological illness. Four of the five sequenced strains belonged to an emerging clade (C1), defined by four novel nonsynonymous mutations in key antigenic epitopes. We recommend reinforced clinical awareness and EV genomic surveillance, including respiratory samples, even when symptoms are neurological.
-
- Top
-
- Research
-
-
-
Molecular screening to track ceftriaxone-resistant FC428-like Neisseria gonorrhoeae strains’ dissemination in four provinces of China, 2019 to 2021
Leshan Xiu , Liqin Wang , Yamei Li , Lihua Hu , Jia Huang , Gang Yong , Youwei Wang , Wenling Cao , Yang Yang , Weiming Gu and Junping PengBackgroundThe global dissemination of ceftriaxone-resistant Neisseria gonorrhoeae FC428-like strains poses a public health concern. To assess and follow their spread, establishing effective antimicrobial resistance (AMR) surveillance systems is essential.
AimThis study aimed to track ceftriaxone-resistant FC428-like strains in parts of China, using a molecular screening tool.
MethodsSamples were collected from Sichuan, Zhejiang, Shanghai, and Guangdong provinces between 2019 and 2021. We employed a rapid molecular tool − the high-resolution melting analysis-based FC428 (HRM-FC428) assay, to screen for FC428-like strains. All FC428-like strains detected were further characterised by genotyping and PCR-sequencing.
ResultsOf 1,042 tested samples, 44 harboured the penA-60.001 allele linked to ceftriaxone resistance, revealing a 4.2% prevalence of FC428-like strains. The HRM-FC428 assay additionally uncovered six strains with mosaic penA-195.001 or penA-232.001 alleles, both bearing the A311V mutation, a ceftriaxone resistance marker. During the study, the prevalence of FC428-like strains among overall samples appeared to increase, with rates of 2.8% (11/395) in 2019, 4.2% (16/378) in 2020, and 6.3% (17/269) in 2021. Some strains’ sequence types (ST)s were identified across provinces (e.g. ST1903, ST1600) and most strains (24/44) were ST1903, an ST also reported in other regions/countries, suggesting local evolution and global transmission.
ConclusionOur work underscores the value of culture-independent antimicrobial resistance monitoring and validates the use of molecular diagnostic tools, like the HRM-FC428 assay for this purpose. This study offers insights into the complex landscape of ceftriaxone-resistant N. gonorrhoeae, emphasising the importance of continued surveillance and global collaboration to mitigate this growing public health threat.
-
-
-
Inferring transmission risk of respiratory viral infection from the viral load kinetics of SARS-CoV-2, England, 2020 to 2021 and influenza A virus, Hong Kong, 2008 to 2012
Jakob Jonnerby , Joe Fenn , Seran Hakki , Jie Zhou , Kieran J Madon , Aleksandra Koycheva , Sean Nevin , Rhia Kundu , Michael A Crone , Timesh D Pillay , Shazaad Ahmad , Nieves Derqui , Emily Conibear , Robert Varro , Constanta Luca , Paul S Freemont , Graham P Taylor , Maria Zambon , Wendy S Barclay , Jake Dunning , Neil M Ferguson , Benjamin J Cowling , Ajit Lalvani and on behalf of the ATACCC Study InvestigatorsBackgroundInfectiousness of respiratory viral infections is quantified as plaque forming units (PFU), requiring resource-intensive viral culture that is not routinely performed. We hypothesised that RNA viral load (VL) decline time (e-folding time) in people might serve as an alternative marker of infectiousness.
AimThis study’s objective was to evaluate the association of RNA VL decline time with RNA and PFU VL area under the curve (AUC) and transmission risk for SARS-CoV-2 and influenza A virus.
MethodsIn SARS-CoV-2 and influenza A virus community cohorts, viral RNA was quantified by reverse transcription quantitative PCR in serial upper respiratory tract (URT)-samples collected within households after an initial household-member tested positive for one virus. We evaluated correlations between RNA VL decline time and RNA and PFU-VL AUC. Associations between VL decline time and transmission risk in index-contact pairs were assessed.
ResultsIn SARS-CoV-2 cases, we observed positive correlations between RNA VL decline time and RNA and PFU VL AUC with posterior probabilities 1 and 0.96 respectively. In influenza A cases a positive correlation between RNA VL decline time and RNA VL AUC was observed, with posterior probability of 0.87. Index case VL decline times one standard deviation above the cohort-mean showed a relative increase in secondary attack rates of 39% (95% credible interval (CrI): −6.9 to 95%) for SARS-CoV-2 and 25% (95% CrI: −11 to 71%) for influenza A virus.
ConclusionWe identify VL decline time as a potential marker of infectiousness and transmission risk for SARS-CoV-2 and influenza A virus. Early ascertainment of VL kinetics as part of surveillance of new viruses or variants could inform public health decision making.
-
Volumes & issues
-
Volume 30 (2025)
-
Volume 29 (2024)
-
Volume 28 (2023)
-
Volume 27 (2022)
-
Volume 26 (2021)
-
Volume 25 (2020)
-
Volume 24 (2019)
-
Volume 23 (2018)
-
Volume 22 (2017)
-
Volume 21 (2016)
-
Volume 20 (2015)
-
Volume 19 (2014)
-
Volume 18 (2013)
-
Volume 17 (2012)
-
Volume 16 (2011)
-
Volume 15 (2010)
-
Volume 14 (2009)
-
Volume 13 (2008)
-
Volume 12 (2007)
-
Volume 11 (2006)
-
Volume 10 (2005)
-
Volume 9 (2004)
-
Volume 8 (2003)
-
Volume 7 (2002)
-
Volume 6 (2001)
-
Volume 5 (2000)
-
Volume 4 (1999)
-
Volume 3 (1998)
-
Volume 2 (1997)
-
Volume 1 (1996)
-
Volume 0 (1995)
Most Read This Month
![Loading](/images/jp/spinner.gif)
-
-
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Victor M Corman , Olfert Landt , Marco Kaiser , Richard Molenkamp , Adam Meijer , Daniel KW Chu , Tobias Bleicker , Sebastian Brünink , Julia Schneider , Marie Luisa Schmidt , Daphne GJC Mulders , Bart L Haagmans , Bas van der Veer , Sharon van den Brink , Lisa Wijsman , Gabriel Goderski , Jean-Louis Romette , Joanna Ellis , Maria Zambon , Malik Peiris , Herman Goossens , Chantal Reusken , Marion PG Koopmans and Christian Drosten
-
- More Less